Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 10/20 | 0.60 |
| ▸ | FLT4 | P35916 | 5/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | CSF1R | P07333 | 4/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.57 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394109 | 1.00 | FLT3 (0.61) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL396158 | 0.93 | CSF1R (0.69) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL10091875 | 0.93 | CSF1R (0.69) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL394230 | 0.93 | FLT3 (0.65) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL10091945 | 0.93 | FLT3 (0.65) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL10091892 | 0.89 | NTRK2 (0.65) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL396405 | 0.89 | NTRK2 (0.65) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL396343 | 0.89 | FLT3 (0.66) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL10091880 | 0.89 | FLT3 (0.66) | FLT3AURKBKDRFLT4KIT | |
| SCHEMBL4133365 | 0.88 | FLT3 (0.77) | FLT3AURKBKDRFLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | FLT3 93/4885AURKB 164/4885KDR 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.